{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:08Z","timestamp":1790830808143,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CGT"],"published-print":{"date-parts":[[2026,9,28]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The convergence of Artificial Intelligence (AI) and Cell and Gene Therapy\n(CGT) represents a frontier in next-generation therapeutic innovation, yet the structural patterns\nof technology convergence within this interdisciplinary field remain poorly characterized. This\nstudy aims to develop a computational framework for predicting which technology linkages are\nmost likely to strengthen within this convergence landscape, thereby providing a data-driven basis\nfor R&amp;D resource allocation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Global patent data in the AI-CGT field were collected to construct a time-series heterogeneous\nnetwork in which International Patent Classification (IPC) codes serve as technology nodes\nand individual patents as knowledge nodes, capturing co-occurrence, affiliation, and citation relationships\namong technologies. At the macro forecasting level, a Temporal Heterogeneous Graph\nNeural Network (THGNN) was employed for link prediction. The model aggregated multi-hop\nneighbor information through meta-paths and leveraged Long Short-Term Memory (LSTM) networks\nto capture technological evolution dynamics, with the aim of identifying IPC pairs with the\nhighest future association weights. At the micro-analysis level, Latent Dirichlet Allocation (LDA)\ntopic modeling was applied to patents associated with the core IPC pairs. The optimal number of\ntopics was determined by combining perplexity curves with inter-topic distance visualization to reveal\nthe key technological content of these IPC associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>The temporal heterogeneous graph neural network model achieved an Area Under the\nCurve (AUC) of 0.7539, Average Precision (AP) of 0.7862, and F1 score of 0.7568 for link prediction.\nBased on this model, multiple high-confidence convergence pathways were identified, among\nwhich the predicted potential for association strengthening between biochemical detection (C12Q1)\nand neural networks (G06N3) and between genetic engineering (C12N15) and neural networks\n(G06N3) received the highest prediction scores (0.89 and 0.80, respectively), suggesting that these\npairs are likely to constitute the primary axes of technology convergence in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The two major convergence directions identified above correspond to the core bottlenecks\nin CGT clinical translation\u2014namely, the precision and safety of gene editing, and the quality\ncontrol and efficacy monitoring of therapeutic products. These findings reveal a patent-based convergence\nlandscape in which AI-related patent classifications increasingly co-occur with both detection\nand therapeutic methods, indicating a trend of AI integration across the diagnostic-totherapeutic\ncontinuum at the level of patent disclosures. The identified convergence directions are\ncomputational predictions based on patent co-occurrence patterns and carry inherent uncertainty;\nthey represent technology convergence signals rather than confirmed implementation. The \"macroprediction\u2013\nmicro-analysis\" bi-level framework proposed in this study provides a quantifiable, interpretable,\nand transferable analytical paradigm for technology opportunity identification in interdisciplinary\npharmaceutical research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study introduces THGNN into technology opportunity prediction in the AI-CGT\nconvergence field and establishes a complete analytical chain from macro-level association identification\nto micro-level technology interpretation through LDA topic modeling. The findings offer a\ndata-driven decision-making reference for pharmaceutical companies and research institutions seeking\nto strategically position their R&amp;D pipelines within complex technology landscapes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115665232515473260910071847","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:44:21Z","timestamp":1790829861000},"source":"Crossref","is-referenced-by-count":0,"title":["Trends and Hotspots in the Convergence of Artificial Intelligence and Cell\nand Gene Therapy: A Patent Analysis"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3477-8385","authenticated-orcid":true,"given":"Hongmei","family":"Yuan","sequence":"first","affiliation":[{"name":"School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1638-5930","authenticated-orcid":true,"given":"Yuandong","family":"He","sequence":"additional","affiliation":[{"name":"School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4659-8322","authenticated-orcid":true,"given":"Cuiyan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-9160","authenticated-orcid":true,"given":"Baijun","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115665232515473260910071847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258850\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115665232515473260910071847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:44:53Z","timestamp":1790829893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258850\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115665232515473260910071847","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}